Pathogenesis of Churg–Strauss syndrome: Recent insights

The emergence of antineutrophil cytoplasmic antibodies may precede the clinical onset of Churg-Strauss syndrome

(2009) Jochen Zwerina et al.   ARTHRITIS AND RHEUMATISM

Treatment of Churg-Strauss syndrome without poor-prognosis factors: A multicenter, prospective, randomized, open-label study of seventy-two patients

(2008) Camillo Ribi et al.   ARTHRITIS AND RHEUMATISM

Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab

(2008) Marc E. Rothenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production

(2008) R. J. Pepper et al.   RHEUMATOLOGY

Eotaxin-3 is involved in Churg-Strauss syndrome - a serum marker closely correlating with disease activity

(2008) K. Polzer et al.   RHEUMATOLOGY

The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study

(2008) T Hauser et al.   THORAX